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Summary We determined the concentrations of immunoreactive epidermal growth factor in the urine
(U-irEGF) of 97 adult patients with various malignancies, including carcinomas of the urinary bladder,
kidney, stomach, colon, rectum, breast, endometrium, uterine cervix, ovary, vagina, prostate, pancreas and
thyroid, liposarcoma and skin melanoma. The relative U-irEGF concentrations (ng m-1 creatinine) were
higher (P=0.002) for the whole series of female patients than for healthy controls matched for sex and age.
Such difference did not appear for male patients. The only specific group with a statistically supranormal
U-irEGF concentration (P=0.0005) comprised women with endometrial carcinoma of the uterus.
Epidermal growth factor (EGF) appears to be involved in the
regulation of proliferation, differentiation and differentiated
functions of a multitude of cell types (Gospodarowicz, 1981;
Carpenter & Zendegui, 1986). In certain normal cells in vitro
EGF elicits transformation-associated responses (Stoscheck
et al., 1986). There is also a considerable body of evidence
associating EGF receptor with oncogenesis. The EGF
receptor is the product of the c-erbB proto-oncogene, which
is closely related to the v-erbB (Downward et al., 1984). The
receptor is present in enormous numbers on the cells of
many human epidermoid and glial malignancies (Lin et al.,
1984; Merlino et al., 1984; Libermann et al., 1984). Many
malignant cells produce another EGF receptor agonist, trans-
forming growth factor alpha (TGF-a) (Todaro et al., 1980;
Roberts et al., 1980). TGF-cx is excreted in urine by patients
with various malignancies (Sherwin et al., 1983), but not by
healthy subjects (Twardzik et al., 1985).
Uchihashi et al. (1983) and Kurobe et al. (1985) found
urinary excretion of EGF to be higher in patients with
cancer than in healthy persons. This has not been generally
accepted. We have now measured urinary immunoreactive
EGF (U-irEGF) levels in patients with a variety of malig-
nancies before and after tumour removal.
Materials and methods
Subjects and samples
Spot urine samples were collected from 97 patients (49 men
and 48 women, aged 28-88 years) with various malignancies
before surgical removal (or any other treatment) of the
tumour. In addition to those shown in Figure 1, six patients
had carcinomas, I of the vagina, 2 of the pancreas, and 3 of
the thyroid, and 1 patient had liposarcoma and 1 skin
melanoma. The malignancies included both metastasized and
in situ tumours. We also measured U-irEGF concentration in
24 patients daily during the first week after removal of the
tumour, and in a further 7 patients on the sixth post-
operative day. For comparison, urine samples were collected
from age- and sex-matched healthy subjects (56 men and 62
women, aged 28-86 years).
Assay procedures
Human EGF, used both as standard and labelled tracer, and
a rabbit antiserum against it (8C-217,3129) were donated by
AMGen (Thousand Oaks, California). U-irEGF was
measured by a specific homologous radioimmunoassay
(Mattila et al., 1985) and creatinine by the kinetic method of
Jaffe (Lustgarten & Wenk, 1972).
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Gel exclusion chromatography
To determine the molecular size of the U-irEGF we used
high-performance gel exclusion chromatography (HPLC) on
a prepacked 7.5 x 300mm blue column TSK G2000 SW
(LKB, Bromma, Sweden) and an LKB 2150 HPLC pump
with a Rheodyne injector, model 7125 (Rheodyne, CA),
equipped with a 100-pl sample loop. The column was
equilibrated and eluted at room temperature with 0.01 M
sodium phosphate buffer (pH 6.8) containing 0.1 M NaCl and
20% acetonitrile (Rathburn HPLC grade S, Walkerburn,
Scotland).
Statistical analysis
Since U-irEGF concentrations in humans are age- and sex-
dependent (Uchihashi et al., 1982; Mattila, 1986), they were
expressed as standard deviation score (SDS), i.e. deviation in
SD units from the mean value of age- and sex-matched
controls. Because of positive skewness of the distributions of
U-irEGF values, all calculations were made after
logarithmic transformation. Tests used were Kruskall-Wallis
H-test, and simple linear correlation and regression analysis
(Dixon, 1981).
Results
To eliminate the effect of variability in the rate of water
excretion, U-irEGF concentrations were expressed in ng per
mg creatinine, as previously established (Dailey et al., 1978;
Mattila et al., 1985). These relative U-irEGF concentrations
of the whole series of female cancer patients were higher
(P=0.002) than those of healthy female controls No such
difference appeared for the male cancer patients (Figure 2).
The only specific group with a mean U-irEGF concentration
higher than in controls, SDS being + 1.3 +0.3
(mean+s.e.m.; P=0.0005, Figure 1), comprised women with
endometrial carcinoma. In no other group did the size and
spreadofthe tumourseem toinfluenceU-irEGFconcentration.
In the women with endometrial carcinoma the relative
U-irEGF concentration did not change significantly after
tumour removal (29.3 +4.2 vs. 25.7+3.5ngmg-1 creatinine,
mean +s.e.m.). Of the female patients with conditions other
than endometrial carcinoma, we had a postoperative sample
only from 6. The concentration did not change significantly
in any other specific group. Patients with renal carcinoma
were an exception; unilateral nephrectomy caused - 50%
decrease in their relative U-irEGF concentrations.
Gel exclusion chromatography revealed no abnormality in
the apparent molecular nature of the urinary irEGF in
patients with endometrial carcinoma. Determined in 4
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Figure 1 SD scores (deviation in SD units from the mean value
for sex and age) of urinary immunoreactive epidermal growth
factor concentrations in individual patients (-, females; *,
males) with different malignancies. The hatched areas indicate
95% confidence intervals of the mean values for each group. The
age range of the patients is given in parentheses. The P value for
significant difference from age- and sex-matched controls (SD
score 0) is given.
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Figure 2 Regression lines of urinary concentration (ngmg-'
creatinine) of immunoreactive epidermal growth factor vs. age in
female (FP) and male cancer patients (MP), and in female (FC)
and male controls (MC). The difference between FP and FC is
significant (P=0.002).
patients a mean of 95% of the immunoreactivity coeluted
with the EGF standard. The rest consisted of high-molecular
weight forms of -20 and 70 kilodaltons.
Discussion
Urinary irEGF concentrations were statistically supranormal
in female cancer patients in general, but as far as specific
patient groups were concerned, only in women with
endometrial carcinoma. In contrast, Uchihashi et al. (1983)
found statistically supranormal urinary immunoreactive EGF
excretion in patients with carcinomas of the lung, maxilla,
oesophagus, stomach, thyroid, breast, and cervix, and in
patients with leukaemia, malignant lymphoma and multiple
myeloma. Likewise, Kurobe et al. (1985) found supranormal
urinary EGF levels in patients with gastric carcinoma.
Neither series included patients with endometrial carcinoma.
Urinary EGF originates mostly from the kidneys (Rall et
al., 1985; Olsen et al., 1984; Mattila et al., 1986). Thus an
increase in urinary EGF concentration could be due to
stimulation of renal EGF production by some tumour-
associated factor. Alternatively, the malignant tumour might
produce irEGF, which is excreted via blood to urine. The
fact that the U-irEGF decreased by -50% after unilateral
nephrectomy, is an expected consequence of its renal origin.
Since the relative U-irEGF concentrations in the patients
with endometrial carcinoma did not decrease after removal
of the tumour, it is unlikely that the cancer produced or
stimulated the production of the excess of U-irEGF. This
excess might rather be another result of some carcinogenic
factor(s) affecting these patients. Development of endometrial
carcinoma has been suggested to be associated with a
preceding supranormal oestrogen production and/or relative
progesterone deficiency (Gambrell, 1986). Female sex steroids
do appear to regulate urinary irEGF excretion. In both
human beings and mice, females excrete more irEGF than
males (Uchihashi et al., 1982; Mattila, 1986; Perheentupa et
al., 1985). Moreover, in mice oestrogen treatment increased
and progesterone treatment decreased U-irEGF
concentration (Tuomela et al., 1985).
The statistically supranormal U-irEGF in the whole series
of female patients is most interesting, but we have no
explanation for this. Evidently it is associated with the fact
that 22 of the 27 patients with female-specific carcinoma had
values above age- and sex-specific mean values of controls.
Against this background the case of endometrial carcinoma
is not unique. Perhaps it was by chance that, of the groups
with female specific tumours, only this category reached
statistical significance.
In conclusion, U-irEGF concentration was statistically
supranormal in the whole series of female cancer patients,
but in groups with specific malignancies only in patients with
endometrial carcinoma. The mechanism of this supranormal
excretion is unknown, but it may be hormonally mediated.
We thank Anne Vikman and Hilkka Salmi for skilful technical
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